Dataset Information


Statin use is associated with reduced risk of haematological malignancies: evidence from a meta-analysis.



Several observational studies have shown that statin use may modify the risk of haematological malignancies. To quantify the association between statin use and risk for haematological malignancies, we performed a detailed meta-analysis of published studies regarding this subject.


We conducted a systematic search of multiple databases including PubMed, Embase, and Cochrane Library Central database up to July 2013. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed.


A total of 20 eligible studies (ten case-control studies, four cohort studies, and six RCTs) reporting 1,139,584 subjects and 15,297 haematological malignancies cases were included. Meta-analysis showed that statin use was associated with a statistically significant 19% reduction in haematological malignancies incidence (RR?=?0.81, 95% CI [0.70, 0.92]). During subgroup analyses, statin use was associated with a significantly reduced risk of haematological malignancies among observational studies (RR?=?0.79, 95% CI [0.67, 0.93]), but not among RCTs (RR?=?0.92, 95% CI [0.77, 1.09]).


Based on this comprehensive meta-analysis, statin use may have chemopreventive effects against haematological malignancies. More studies, especially definitive, randomized chemoprevention trials are needed to confirm this association.

PROVIDER: S-EPMC3909054 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3462187 | BioStudies
| S-EPMC7484024 | BioStudies
| S-EPMC6590158 | BioStudies
| S-EPMC4056771 | BioStudies
2017-01-01 | S-EPMC5650431 | BioStudies
2019-01-01 | S-EPMC6657066 | BioStudies
| S-EPMC3808274 | BioStudies
| S-EPMC3325242 | BioStudies
| S-EPMC4809483 | BioStudies
| S-EPMC5837543 | BioStudies